Morphic Announces Participation in 2022 Jefferies London Healthcare Conference

Rhea-AI Summary

Morphic Therapeutic (Nasdaq: MORF) announced that President Dr. Bruce Rogers will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 10:55 AM GMT. This event highlights Morphic's commitment to its innovative oral integrin therapies for serious chronic diseases, including autoimmune and cardiovascular conditions. Investors can access the live webcast through the Investor section of Morphic's website, with an archived replay available post-conference. For additional details about Morphic and its advancements, visit their official site.

Positive

• Participation at Jefferies London Healthcare Conference enhances company visibility.
• Showcases ongoing commitment to developing innovative oral integrin therapies.

Negative

• None.

News Market Reaction – MORF

+0.91%

+0.91% Session move

In the trading session that priced this news, MORF gained 0.91%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Dr. Bruce Rogers, President of Morphic, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 16^th, at 10:55 AM GMT.

A live webcast of the event will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.

About Morphic Therapeutic

Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. In collaboration with Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718

FAQ

When is Dr. Bruce Rogers speaking at the Jefferies London Healthcare Conference?

Dr. Bruce Rogers will participate in the conference on November 16, 2022, at 10:55 AM GMT.

How can I access the webcast of the Jefferies London Healthcare Conference?

The webcast can be accessed through the Investor section of Morphic Therapeutic's website.

What is the focus of Morphic Therapeutic's research?

Morphic Therapeutic is focused on developing oral integrin therapies for chronic diseases, including autoimmune and cardiovascular diseases.